Patient Selection For Port Delivery Device

Opinion
Video

Panelists discuss how patients experiencing a high treatment burden with frequent anti-VEGF injections every 4-8 weeks are optimal candidates for the port delivery system, which can help reduce their number of clinic visits while maintaining therapeutic effectiveness.

Video content above is prompted by the following:

  • Which patients are ideal candidates for this anti-VEGF delivery method?
  • Patients with frequent anti-VEGF treatment burden (4-8 weeks)
Recent Videos
2 experts in this video
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
AAO 2024: Bonnie An Henderson, MD, talks about advancing medical education with AI, robotics, and diverse learning methods
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Related Content
Systane Ultra PF voluntary recall: Protecting patients from potential risk of fungal material in one lot

Systane Ultra PF voluntary recall: Protecting patients from potential risk of fungal material in one lot

Lynda Charters;Sheryl Stevenson
December 27th 2024
Article

Alcon Laboratories is voluntarily recalling one lot (Lot 10101) of its Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, after identifying fungal contamination in a sealed vial.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A picture of a scale on a laptop computer. One side of the scale holds a human brain, the other holds a laptop, symbolising artificial intelligence. Image credit: ©Who is Danny – stock.adobe.com

Balancing the promises and challenges of artificial intelligence

Polat Goktas, PhD;Andrzej Grzybowski, MD, PhD, MBA, MAE
December 18th 2024
Article

Sophisticated programmes require an evolving mindset

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Bottles of essential oils are placed next to an essential oil aromatherapy diffuser in a calm, warm, spa-like environment. Image credit: ©Botamochy – stock.adobe.com

Adding aromatherapy to recovery protocol may decrease postoperative anxiety and pain

Lynda Charters
November 8th 2024
Article

Following oculoplastic surgery, patients who underwent aromatherapy had shorter stays in the post-anesthesia care unit

A black box in a dark room is opened slightly. The lid is displaced and a red light glows inside. Image credit: ©alastis – stock.adobe.com

The “black box” of artificial intelligence in ophthalmology

Johan Blanckaert, MD
October 7th 2024
Article

Making the most of AI means letting go of fear, says Editorial Advisory Board member Johan Blanckaert, MD

© 2025 MJH Life Sciences

All rights reserved.